AstraZeneca, along with its biologics research and development arm MedImmune, announced positive overall survival results for the Phase III PACIFIC trial on Friday. The FTSE 100 drugmaker described PACIFIC as a randomised, double-blinded, placebo-controlled, multi-centre trial of Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer (NSCLC), whose disease had not progressed following platinum-based chemotherapy concurrent with radiation therapy (CRT). It said a ...Den vollständigen Artikel lesen ...